98%
921
2 minutes
20
Introduction: Burn patients are at high risk for infections, particularly Methicillin-resistant aureus (MRSA). Universal decolonization strategies have demonstrated effectiveness in reducing infection rates. This study aimed to evaluate the cost implications of using pure hypochlorous acid (pHA) and mupirocin to prevent MRSA infections in hospitalized burn patients.
Methods: A patient-level microsimulation model was developed to perform a cost analysis from the US health system perspective. Clinical inputs were derived from a retrospective observational study. The primary outcome was the reduction in MRSA infections per 1,000 bed days. Cost estimates, expressed in 2023 US dollars, were gathered through a pragmatic literature review of publicly available sources. Deterministic and probabilistic sensitivity analyses were conducted to assess the robustness of the findings.
Results: Before the introduction of pHA, burn patients were 3.05 times more likely to develop MRSA infections. The estimated cost of treating MRSA infections was $224,376 per 1,000 bed days in the pre-pHA period, compared to $148,812 in the post-pHA period. After including the cost of pHA, the net savings amounted to $75,564 per 1,000 bed days, or $75.56 per bed day. Sensitivity analyses confirmed the robustness of these results across a range of input values.
Conclusion: The combination of pHA and mupirocin appears to be a cost-saving strategy for reducing MRSA infections among hospitalized burn patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12208844 | PMC |
http://dx.doi.org/10.3389/fphar.2025.1606589 | DOI Listing |
Mol Biol Rep
September 2025
Department of Medical Lab Technology, College of health and medical technology, Sulaimani Polytechnic University, Sulaimani, 46001, Kurdistan Region, Iraq.
Background: Sinusitis is a common respiratory infection increasingly associated with antibiotic-resistant Staphylococcus aureus, posing significant treatment challenges. The emergence of methicillin-resistant S. aureus (MRSA) in sinus infections necessitates comprehensive profiling of resistance patterns to guide effective therapy.
View Article and Find Full Text PDFInfect Control Hosp Epidemiol
September 2025
Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Case Rep Med
September 2025
Oral and Maxillofacial Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Oral and maxillofacial space infection (OMSI) progresses rapidly, and when combined with diabetic ketoacidosis (DKA), it can become a serious and life-threatening condition. Cases of OMSI with concurrent DKA are relatively rare. This case report describes a young man who developed OMSI caused by methicillin-resistant in the setting of DKA.
View Article and Find Full Text PDFMed Int (Lond)
August 2025
Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China.
Punicalagin, a polyphenolic compound extracted from pomegranate peel, has received increasing attention in recent years due to its antibacterial and antiviral properties. Punicalagin is capable of inhibiting bacterial growth at sub-inhibitory concentrations by affecting cell membrane formation, disrupting membrane integrity, altering cell permeability, affecting efflux pumps, interfering with quorum sensing and influencing virulence factors. Additionally, punicalagin inhibits viruses by modulating enzyme activity, interacting with viral surface proteins, affecting gene expression, blocking viral attachment, disrupting virus receptor interaction and inhibiting viral replication.
View Article and Find Full Text PDFBiochem Pharmacol
September 2025
Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Institute of Translational Medicine, Zhejiang Shuren University, 310015 Hangzhou, China. Electronic address:
Methicillin-resistant Staphylococcus aureus (MRSA) is a highly virulent and drug-resistant pathogen frequently causing bacterial pneumonia. Currently, there are limited effective treatments available due to the rapidly evolving resistance of bacteria. Therefore, there is an urgent need to develop novel therapies that focus on host-pathogen interactions.
View Article and Find Full Text PDF